Attention Intellia Therapeutics Investors: Important Information Regarding a Securities Class Action Lawsuit
New York, NY – Rosen Law Firm, a leading investor rights law firm, is reminding purchasers of Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between July 30, 2024, and January 8, 2025, both dates inclusive (the “Class Period”), of the significant April 14, 2024, lead plaintiff deadline.
What Happened to Intellia Therapeutics during the Class Period?
Intellia Therapeutics is a leading gene editing company that develops proprietary CRISPR/Cas9 technology for therapeutic and industrial applications. During the Class Period, Intellia Therapeutics issued several positive press releases regarding its clinical trials and partnerships. However, on January 11, 2025, the company disclosed that one of its clinical trials, the HARMONY study, had been placed on clinical hold due to safety concerns. This news sent the stock price plummeting, causing significant losses for investors.
Why Should I Care if I Purchased Intellia Securities During the Class Period?
If you purchased Intellia securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The securities class action lawsuit alleges that Intellia Therapeutics and certain of its executives and directors made false and/or misleading statements and/or failed to disclose material adverse facts about the company’s HARMONY study and the safety concerns that had arisen.
How Will This Affect Me?
If you purchased Intellia securities during the Class Period and have suffered losses, you may be able to join the class action lawsuit as a lead plaintiff. As a lead plaintiff, you will be a representative party for all other members of the class. This means that you will help make important decisions about the litigation and will be entitled to a portion of the recovery. If you wish to serve as a lead plaintiff, you must apply before the April 14, 2024, lead plaintiff deadline. To be eligible for inclusion in the class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent class member. The class in this case includes all persons who purchased or otherwise acquired Intellia securities between July 30, 2024, and January 8, 2025, both dates inclusive.
How Will This Affect the World?
The outcome of this class action lawsuit could have significant implications for the gene editing industry and the biotech sector as a whole. The case will provide important guidance for investors regarding the disclosure obligations of public companies, particularly in the context of clinical trials and regulatory issues. Moreover, it could lead to increased scrutiny of Intellia Therapeutics and its competitors, potentially impacting their stock prices and market capitalization. Ultimately, the case may help ensure that companies provide full and accurate disclosures to investors, promoting transparency and trust in the financial markets.
Conclusion
If you purchased Intellia Therapeutics securities during the Class Period and have suffered losses, you may be entitled to compensation through a securities class action lawsuit. The April 14, 2024, lead plaintiff deadline is fast approaching, so it is crucial that you take action if you wish to serve as a lead plaintiff. The outcome of this case could have significant implications for the gene editing industry and the biotech sector, as well as for investors in public companies more broadly. For more information about the case or to discuss your potential recovery, please contact Rosen Law Firm at (212) 614-5441 or by email at [email protected].
- Intellia Therapeutics Class Action Lawsuit
- Lead Plaintiff Deadline: April 14, 2024
- Purchasers of Intellia securities between July 30, 2024, and January 8, 2025
- Compensation without out-of-pocket fees or costs
- False and/or misleading statements and/or failure to disclose material adverse facts
- Impact on the gene editing industry and the biotech sector
